NeoGenomics, Inc. - Common Stock (NQ:NEO)

16.64 -0.61 (-3.54%)

Delayed Quote Updated: 1:07 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

19 20 Next >

Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

December 28, 2023

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.

Via Benzinga

US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit ↗

December 28, 2023

Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from

Via Benzinga

Stocks Edge Higher As End Of 2023 Approaches ↗

December 28, 2023

The SPX is less than 10 points away from record close territory, and with one day left, all three major indexes are heading toward sizable December wins.

Via Talk Markets

7 Analysts Have This To Say About NeoGenomics ↗

December 28, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About NeoGenomics ↗

November 07, 2023

Via Benzinga

NeoGenomics Reports Third Quarter 2023 Results

November 06, 2023

Via ACCESSWIRE

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 28, 2023

Via Benzinga

NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday ↗

December 28, 2023

U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ: NEO) shares fell sharply during Thursday’s session after Natera won a...

Via Benzinga

NeoGenomics to Appeal Ruling

December 28, 2023

Via ACCESSWIRE

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

December 05, 2023

Via ACCESSWIRE

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Where NeoGenomics Stands With Analysts ↗

October 16, 2023

Via Benzinga

4 Analysts Have This to Say About NeoGenomics ↗

August 21, 2023

Via Benzinga

NeoGenomics Raises Annual Guidance After Solid Q2 Earnings Beat ↗

August 08, 2023

NeoGenomics, Inc. (NASDAQ: NEO) reported Q2 revenues of $146.92 million, +18% Y/Y, beating the

Via Benzinga

NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference

November 14, 2023

Via ACCESSWIRE

Bull Of The Day: NeoGenomics ↗

October 24, 2023

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.

Via Talk Markets

NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

October 24, 2023

Via ACCESSWIRE

NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023

October 17, 2023

Via ACCESSWIRE

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

October 17, 2023

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END

Via FinancialNewsMedia

NeoGenomics Reports Second Quarter 2023 Results

August 08, 2023

Via ACCESSWIRE

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 08, 2023

Via Benzinga

Earnings Scheduled For August 11, 2023 ↗

August 11, 2023

Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million.

Via Benzinga

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

July 27, 2023

Via ACCESSWIRE

NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

July 18, 2023

Via ACCESSWIRE

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

June 29, 2023

Via ACCESSWIRE

Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark ↗

June 23, 2023

On Friday, Guardant Health stock hit a key performance benchmark, with its Relative Strength Rating rising to 82, up from 78 the day before.

Via Investor's Business Daily

NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

June 15, 2023

Via ACCESSWIRE

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

June 05, 2023

Via ACCESSWIRE

NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

June 01, 2023

Via ACCESSWIRE

NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

May 30, 2023

Via ACCESSWIRE

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.